Alpha 2.0
Login Register
» Authors » Wonngarm Kittanamongkolchai

Wonngarm Kittanamongkolchai

Explore the profile of Wonngarm Kittanamongkolchai including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 74
Citations 959
Followers 0
Related Specialties
Nephrology
General Medicine
Rheumatology
Top 10 Co-Authors
Wisit Cheungpasitporn
Narat Srivali
Charat Thongprayoon
Patompong Ungprasert
Stephen B Erickson
Yingyos Avihingsanon
Michael A Mao
Kianoush B Kashani
Kevin L Greason
Peter J Edmonds
Published In
Am J Emerg Med
Nephrology (Carlton)
Kidney Int
Lupus Sci Med
Ren Fail
Affiliations
Soon will be listed here.
Recent Articles
1.
Effect of a transtheoretical model-based intervention and motivational interviewing on hyperphosphatemia management via telehealth (TMT program) among hemodialysis patients during the COVID-19 pandemic
Thongsunti A, Silpakit C, Rattananupong T, Kittanamongkolchai W, Sumethpimolchai W, Lohsoonthorn V
Front Public Health . 2024 Dec; 12:1361778. PMID: 39668955
Background: Hyperphosphatemia poses a significant risk for cardiovascular diseases and mortality in hemodialysis patients. Non-adherence to phosphate binders and a low-phosphate diet behavior contribute to this issue. Leveraging psychological and...
2.
Phase II prefusion non-stabilised Covid-19 mRNA vaccine randomised study
Puthanakit T, Prompetchara E, Gatechompol S, Ketloy C, Thitithanyanont A, Jongkaewwattana A, et al.
Sci Rep . 2024 Jan; 14(1):2373. PMID: 38287068
ChulaCov19 mRNA vaccine demonstrated promising phase 1 results. Healthy adults aged 18-59 years were double-blind randomised 4:1 to receive two intramuscular doses of ChulaCov19 50 µg or placebo. Primary endpoints...
3.
Therapeutic drug monitoring of mycophenolic acid and clinical outcomes of lupus nephritis: a systematic review and meta-analysis
Wuttiputhanun T, Naiyarakseree N, Udomkarnjananun S, Kittanamongkolchai W, Asada L, Chariyavilaskul P, et al.
Lupus Sci Med . 2024 Jan; 11(1). PMID: 38233072
Introduction: Mycophenolic acid (MPA) is a primary immunosuppressive agent used in the treatment of lupus nephritis (LN). While therapeutic drug monitoring (TDM) of MPA is well established in organ transplantation,...
4.
Effect of canagliflozin in non-diabetic obese patients with albuminuria: A randomized, double-blind, placebo-controlled trial
Greeviroj P, Puapatanakul P, Phannajit J, Takkavatakarn K, Kittanamongkolchai W, Boonchaya-Anant P, et al.
Clin Nephrol . 2023 Sep; 100(5):224-230. PMID: 37675488
Background: Sodium-glucose co-transporter 2 inhibitor (SGLT2i) has been shown to improve renal outcomes in both diabetic and non-diabetic kidney disease. However, the effect of SGLT2i on renal outcomes in patients...
5.
Complement Factor I Gene Variant in an Atypical Hemolytic Uremic Syndrome Triggered by Hypereosinophilia Syndrome
Banjongjit A, Kittanamongkolchai W, Kanjanabuch T
Nephron . 2023 Aug; 147(11):701-706. PMID: 37611541
Atypical hemolytic uremic syndrome (aHUS) is a condition characterized by acute kidney injury (AKI), thrombocytopenia, and microangiopathic hemolytic anemia secondary to complement pathway dysregulation. Several triggers have been identified as...
6.
Safety and immunogenicity of a prefusion non-stabilized spike protein mRNA COVID-19 vaccine: a phase I trial
Gatechompol S, Kittanamongkolchai W, Ketloy C, Prompetchara E, Thitithanyanont A, Jongkaewwattana A, et al.
Nat Microbiol . 2022 Nov; 7(12):1987-1995. PMID: 36376393
Effective mRNA SARS-CoV-2 vaccines are available but need to be stored in freezers, limiting their use to countries that have appropriate storage capacity. ChulaCov19 is a prefusion non-stabilized SARS-CoV-2 spike-protein-encoding,...
7.
Benefits of Switching Mycophenolic Acid to Sirolimus on Serological Response after a SARS-CoV-2 Booster Dose among Kidney Transplant Recipients: A Pilot Study
Banjongjit A, Phirom S, Phannajit J, Jantarabenjakul W, Paitoonpong L, Kittanamongkolchai W, et al.
Vaccines (Basel) . 2022 Oct; 10(10). PMID: 36298550
Kidney transplant recipients (KTRs) have a suboptimal immune response to COVID-19 vaccination due to the effects of immunosuppression, mostly mycophenolic acid (MPA). This study investigated the benefits of switching from...
8.
Immunogenicity of the third and fourth BNT162b2 mRNA COVID-19 boosters and factors associated with immune response in patients with SLE and rheumatoid arthritis
Assawasaksakul T, Sathitratanacheewin S, Vichaiwattana P, Wanlapakorn N, Poovorawan Y, Avihingsanon Y, et al.
Lupus Sci Med . 2022 Jul; 9(1). PMID: 35902168
Objectives: To evaluate the safety and immunogenicity of third and fourth BNT162b2 boosters in patients with SLE and rheumatoid arthritis (RA). Methods: Patients with SLE and RA aged 18-65 years...
9.
Comparison of Immunogenicity and Safety of Inactivated, Adenovirus-Vectored, and Heterologous Adenovirus-Vectored/mRNA Vaccines in Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis: A Prospective Cohort Study
Assawasaksakul T, Lertussavavivat T, Sathitratanacheewin S, Oudomying N, Vichaiwattana P, Wanlapakorn N, et al.
Vaccines (Basel) . 2022 Jun; 10(6). PMID: 35746461
Background: Impaired immune responses to COVID-19 vaccines have been observed in autoimmune rheumatic disease patients. Determining the most effective and safe vaccine regimen is critically needed in such a population....
10.
Pharmacokinetics and pharmacodynamics profiles of enteric-coated mycophenolate sodium in female patients with difficult-to-treat lupus nephritis
Chariyavilaskul P, Phaisal W, Kittanamongkolchai W, Rukrung C, Anutrakulchai S, Avihingsanon Y
Clin Transl Sci . 2022 May; 15(7):1776-1786. PMID: 35570339
Relapsed or resistant lupus nephritis (LN) is considered a difficult-to-treat type of LN, and enteric-coated mycophenolate sodium (EC-MPS) has been used in this condition. Therapeutic drug monitoring using the area...